Scientist: Tatiana Prowell, M.D.
Dr. Tatiana Prowell is breast cancer scientific liaison in the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration (FDA) and associate professor of oncology in the Breast Cancer Program at the Johns Hopkins Kimmel Comprehensive Cancer Center. She was the principal architect of the FDA’s policy on accelerated approval using pathological complete response as a novel regulatory endpoint in the neoadjuvant high-risk breast cancer setting, and was a member of the Cancer Moonshot Blue Ribbon Panel Cancer Immunology Working Group.
She is a three-time recipient of the FDA’s Excellence in Communication Award, as well as a Giants of Cancer Care Award finalist. A passionate medical educator and mentor, she currently serves on the faculty of the Vail Methods in Clinical Cancer Research Workshop, the Accelerating Anti-Cancer Agent Development and Validation (AAADV) Workshop, the FDA/ASCO Fellows’ Day Workshop, the Society for Translational Oncology Fellows’ Forum, and the Dana Farber Clinical Investigator Seminar Series, among others. She sees patients in the Johns Hopkins Second Opinion Breast Cancer Clinic and teaches in the medical school and medical oncology fellowship training program.